The Real Costs of Rare Disease
Congenica welcomed an expert panel to discuss the true cost of rare disease, from birth to diagnosis, childhood to adulthood.
Global barriers to genomics - Malaysian Epilepsy Conference
A look at the barriers to genomics around the world, starting with a webinar in Malaysia, ‘Epilepsy Advocacy: Challenges and Opportunities’.
Whole Genome Sequencing at Birth: What Should Be Looked For?
Dr Charles Steward speaks to the Progress Educational Trust about “Whole Genome Sequencing at Birth: What Should Be Looked For? What Should Be Fed Back?”.
Why choose a professional solution for your genomic data analysis?
Congenica survey illustrates the severity and impact of specific challenges in clinical genomics practice, especially genomic analysis and reporting.
Opening the Black Box: Telling the Story of a Genomic Diagnosis
Congenica opens the Black Box, following the journey of Karen Lettington and her son George as they are enrolled in the 100k Genomes Project
100k Genomes Pilot on Rare Disease Diagnosis in Healthcare
Co-author reviews the 100,000 Genomes Pilot on rare disease diagnosis in healthcare – Preliminary Report, published in New England Journal of Medicine
Enabling Genomic Medicine 2021
EGM 2021 featured some of the world's leading experts in precision medicine discussing the latest innovations in genomics. Watch their presentations here.
Automating Clinical Genomic Analysis & Reporting for Rapid NGS Results
With the increasing access to exome and genome testing the interpretation of this data is taking longer and longer.
Congenica signs distribution agreement with ATC Healthcare in Turkey
Congenica announces new distribution agreement with ATC Healthcare, a Turkish business investing in advanced tech in molecular diagnosis & life sciences.
Science, genomics hope and a father's love
Congenica’s PAE Lead Charles Steward is guest on ‘Making our Way’ podcast, a place for conversations about some of the toughest and best moments in life.
Congenica contributes to the BIA's Genomics Nation report
Congenica joins the BIA's report looking at the strength, breadth and opportunity of the UK genomics sector for investors, patients and the economy.
Unleash Molecular Superpowers with Next-Generation Genomic Analysis
NGS data analysis software augments molecular medicine powers so more patients can be diagnosed and treated